The lawsuit was brought about by Truvada manufacturer Gilead Sciences. On May 2, 2018 the FDA ruled that PrEP should be available for all ages without restriction and started their first-ever generic process (meaning no patent). This meant that anyone could now make a lower cost version of Truvada at any time which would bring down the price from $84 per month to as low as $1,000 per year.